Effect of Promotional Literature on the Prescribing Habits of Practitioners
Center Watch. FDA Approved Drugs Year 2015. Available from: http:// www.centerwatch.com /druginformation/ fda-approved-drugs. Accessed on Feb.3rd, 2015.
Ministry of Health and Family Welfare, Government of India. List of New Drugs Approved for Marketing in India in Year 2014. Available from: http://www.cdsco.nic.in/ forms/list.aspx? lid=1820&Id=11.Accessed on Feb.3rd, 2015.
Figueiras A, Caamano F, Gestal Otero JJ. Incentives for doctors from the pharmaceutical industry: ethical problems, limits, and alternatives. Gac Sanit 1997 NovDec;11(6):297-300.
Hull FM, Marshall T. Sources of information about new drugs and attitudes towards drug prescribing: an international study of differences between primary care physicians. Fam Pract 1987 Jun;4(2):123-8.
Different Types of Scientific Literature. Available from: https://www.um.edu.mt/__data/assets/file/0006 /42981/The_different _types_of_scientific_literature.pdf. Accessed on Jan. 26th, 2015.
University of Minnesota -Health Science Library. Primary, Secondary and Tertiary Sources in the Health Sciences. Available from: http://hsl.lib.umn.edu/biomed/ help / primary-secondary-and-tertiary-sourceshealthsciences. Accessed Mar.26, 2015.
Forbes. The Cost Of Creating A New Drug Now $5 Billion, Pushing Big Pharma To Change. Available from: http://www.forbes.com/sites/christopherh elman/2015/09/12 / big-oil-ceo-a-fewpeopleare-going-to-drown. Accessed on Jun.11, 2015.
IMS Health. US Promotional Spend by Type – IMS Health. Available from: http://www.imshealth.com/ deployed files/ims/Global/Content/Corporate/ Press%20Room/Top-Line%20Market% 20Data%20&%20Trends/2011%20Topline% 20Market%20Data/Promo_ Spend_ By _ Type.pdf. Accessed on Aug.8th, 2015.
Sagar A, Socolar D. Drug industry marketing staff soars while research staffing stagnates. Report. Boston University School of Public Health, December 2001.
McGettigan P, Golden J, Fryer J, Chan R, Feely J. Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message. Br J Clin Pharmacol 2001 Feb;51(2):184-9.
Oshikoya KA, Oreagba I, Adeyemi O. Sources of drug information and their influence on the prescribing behavior of doctors in a teaching hospital in Ibadan, Nigeria. Pan Afr Med J 2011;9:13.
Vancelik S, Beyhun NE, Acemoglu H, Calikoglu O. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey.BMC Public Health 2007 Jun 25;7:122.
Ben Abdelaziz A, Harrabi I, Rahmani S, Gaha R, Ghannem H. Circulation of pharmaceutical information among general practitioners in the region of Sousse(Tunisia). Therapie 2002 MayJun;57(3):229-35.
Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995 Apr 26;273(16):1296-8.
Shaughnessy AF, Slawson DC, Bennett JH. Separating the wheat from the chaff: identifying fallacies in pharmaceutical promotion. J Gen Intern Med 1994 Oct;9(10):563-8.
Essential Drugs Monitor No. 031 (2002). WHO 2002.Available from: http://apps.who. int/medicinedocs /en/d/Js4937e/. Accessed on Jul.31, 2015.
Carrin G. Drug prescribing: a discussion of its variability and (Ir) rationality. Health Policy 1987 Feb;7(1):73-94.
Payer L. Disease mongers: How doctors, drug companies and insurers are making you feel seek. New York: Willey and Sons; 1992.p. 292.
Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992 Jul;102(1):270-3.
Mapes R. Aspects of British general practitioners' prescribing. Med Care 1977 May;15(5):371-81.
Manchanda P, Honka E. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics 2005;5(2):785-822.
- There are currently no refbacks.